Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-12-06 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos increases share capital through subscription right exercises
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an increase in share capital due to the exercise of subscription rights, resulting in the issuance of 22,600 new ordinary shares. It details the resulting total share capital and the total number of voting rights. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), an interim report (IR), or a proxy statement (PSI).
2021-12-06 English
6-K Filing
Regulatory Filings
2021-12-06 English
Galapagos increases share capital through subscription right exercises.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an increase in share capital due to the exercise of subscription rights, resulting in the issuance of 22,600 new ordinary shares. It details the resulting total share capital and the total number of voting rights. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), an interim report (IR), or a proxy statement (PSI).
2021-12-04 English
Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a capital increase ('kapitaalverhoging') resulting from the exercise of subscription rights ('uitoefening van inschrijvingsrechten'). It details the number of new shares issued, the total capital raised, and updates the total number of voting securities and capital structure, referencing Belgian transparency legislation. This content directly relates to changes in the company's financing and capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP).
2021-12-04 Dutch
6-K Filing
Regulatory Filings
2021-11-29 English
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Earnings Release Classification · 95% confidence The document is a press release from Galapagos NV dated November 22, 2021, announcing the completion of patient recruitment for the MANGROVE Phase 2 study involving GLPG2737 for ADPKD. It details the study design, mechanism of action, expected results timeline (H1 2023), and includes standard sections like 'About ADPKD', 'About Galapagos', contact information, and forward-looking statements. This format is characteristic of an Earnings Release (ER) or a general press release announcing significant operational milestones, rather than a comprehensive regulatory filing like a 10-K or IR. Since it is an announcement of key operational/clinical progress and includes financial/investor contacts, it fits best under the Earnings Release (ER) category, which often encompasses major operational updates outside of formal quarterly/annual reports. It is not a transcript (CT), a formal report (AR, IR), or a proxy statement (DEF 14A/PSI). Given the content focuses on clinical trial progress and future results expectations, ER is the most appropriate fit among the provided options for a major corporate announcement. Q4 2021
2021-11-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.